Funding for this research was provided by:
Puma Biotechnology Inc.
Text and Data Mining valid from 2019-02-27
Received: 30 July 2018
Accepted: 31 January 2019
First Online: 27 February 2019
Ethics approval and consent to participate
: The study was approved by institutional review boards/independent ethics committees at each site, and all patients provided written informed consent.
: Not applicable.
: JM has performed a consulting or advisory role for Puma Biotechnology (ExteNET Data and Safety Monitoring Board). JdP has stock or other ownership in Novobiotics and Creatics, has received honoraria from Braintree Laboratories and Takeda, performed a consulting or advisory role for Braintree Laboratories and speakers’ bureaus for Takeda and AstraZeneca, and is a member of the ExteNET Data and Safety Monitoring Board. KS has performed a consulting or advisory role for Puma Biotechnology (ExteNET Data and Safety Monitoring Board). YY is a former employee of Puma Biotechnology and owns stock in Puma Biotechnology and Amgen. MJ has received honoraria from Foundation Medicine; performed consulting or advisory roles for Novartis; Genentech, Lilly, Bristol-Myers Squibb, and Pfizer; received research funding from Genentech, Ariad, Clovis Oncology, and AbbVie, travel and accommodation expenses from Novartis, Genentech, Lilly, Ariad, Pfizer, and Bristol-Myers Squibb; and is a member of the ExteNET Data and Safety Monitoring Board for Puma Biotechnology.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.